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Abstract
Background: In their paper “Research approvals iceberg: how a ‘low-key’ study in England needed 89 professionals
to approve it and how we can do better” Petrova and Barclay highlight concerns with the health research
regulatory environment in the UK.
Discussion: As long-standing chairs of NHS research ethics committees, researchers, and also academics in research
ethics, we are also often frustrated with the regulatory process in the UK. However, we think that Petrova and
Barclay’s analysis is misleading because it conflates research ethics with governance and funding processes, thus
failing to adequately distinguish between the national coordinating function of the Health Research Authority, local
research governance processes, and interactions with research sponsors and/or the Clinical Research Network.
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Holding regulatory authorities and systems to account
is an important and valid task. As research is an
inherently complex and difficult process, more must
and can always be done to support academics and cli-
nicians to successfully navigate the landscape. Layers
of complex bureaucracy do not help anyone. Yet crit-
ical historical failings and criminal activities have cre-
ated the need for robust integrity, ethics and
governance processes. The challenge is to find the
balance between a system able to effectively prevent
the failings of the past, and yet at the same time not
turn the research process into an impenetrable quag-
mire that inhibits the production of important know-
ledge. The first aim of regulatory processes is
therefore “to protect and promote the interests of
patients and the public” [1], but the second should be
to promote and support good research. Critically
reviewing and quantifying the research regulatory pro-
cesses so as to hold systems and administrators to
account is an important task. In their paper “Research
approvals iceberg: how a ‘low-key’ study in England
needed 89 professionals to approve it and how we
can do better” [2] Petrova and Barclay provide a brief
review of the literature on “RECs (Research Ethics
Committees), IRBs (Institutional Review Boards) and
ethics approvals for health research” before attempt-
ing to list the individuals, exchanges and emails
required to get a single project underway in the UK’s
National Health Service (NHS) setting. As described
the results are shocking, but the paper contains a key
misunderstanding by conflating different systems and
processes.
Distinguishing between research ethics and
research governance
In 2017 the UK House of Commons Science and Tech-
nology Select Committee launched an inquiry into
research integrity [3]. This was partly in response to an
influential 2014 report by the Nuffield Council on Bio-
ethics [4] examining the culture of research in the UK in
an attempt to address “fears that the ‘publish or perish’
culture leads to poor or questionable research practices”
[5]. Over 80 written submissions were made to the select
committee that were subsequently made available on the
committee website [6]. One of us (SEK) used these sub-
missions as raw data for training students in the conduct
and use of basic content analysis. Although this analysis
was conducted as a training exercise not intended for
publication, it was found anecdotally that there was sig-
nificant confusion in the submissions between the terms
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“governance”, “integrity” and “ethics”. This was notable
because submissions to the inquiry were made by
research councils, universities, charities, learned organi-
sations, academics and groups with a strong interest in
the scientific method and process; in other-words expert
organisations that were familiar with the practice, social
and political aspects of Science as practised in the UK.
This is concerning because it leads to the conflation of
functions and roles, and significant confusion as to who
is responsible, and ultimately accountable, for different
parts of the system. The paper by Petrova and Barclay
reflects this confusion, and provides a helpful opportun-
ity to illustrate, in particular, the differences between re-
search governance and research ethics.
To their credit Petrova and Barclay do refer to both
ethics and governance in their abstract and introduction,
followed by stating:
A further clarification of scope and terminology may be
helpful. Most of the background literature addresses the
ethics approvals of studies. However, study approvals are
a broader enterprise, variably termed (at least in the
UK) “research ethics and governance approvals”, “ethics
and R&D (research and development) approvals”, “study
assurances”, etc. Additional sign-offs are needed by R&D
departments of participating organisations or university
research offices (if the ethics approval has been granted
by a committee unattached to a university) around com-
pliance with regulations or the capacity of an organisa-
tion to host a project. Researchers involved in human
subjects research often use “ethics approvals” as a synec-
doche for this broader class of research ethics and govern-
ance approvals, not least because the latter are typically
contingent on the former and because the bulk of the
documentation is first prepared for the ethics review…
The authors’ recognition of this distinction between
ethics and governance is extremely important, so it is
disappointing that they finish this paragraph by stating
that they will conflate the two as:
… Our paper concerns this broader class of approvals.
This is a significant mistake as it fails to recognise the
distinct roles of governance and ethics, and the fact that
each has a slightly different philosophical and practical
contribution to the conduct of “good science”. Indeed it
is one of the strengths of the UK system that ethics re-
view and governance processes are separated, unlike the
Institutional Review Board (IRB) system in the United
States whose main weakness (in our opinion) is also
conflating these two areas. We therefore agree with
them that “ethical dilemmas are amongst the most en-
gaging and enlivening topics of conversation” because
this is precisely our experience of chairing research eth-
ics committees. However, we disagree that the role of
research ethics committees in particular is “hardly ever
about ethical deliberation” or “caring about ethical con-
duct only insofar as litigation and reputational damage
can be avoided”. This may (or may not) be true of the
regulatory process overall, but certainly does not accur-
ately describe the attitude or experience of research
ethics committees.
Research ethics
Within the current NHS system the task of the research
ethics committee is the review of a specific protocol by
up to 16 individuals consisting of both lay and expert
members. We have previously described both the con-
tent and weaknesses of such reviews (and suggested
areas for further research into how RECs make deci-
sions) [7], but essentially these committees have the role
of assessing whether the project, if conducted as
described in the protocol, Integrated Research Applica-
tion System (IRAS) form and related documentation [8],
is ethical; firstly for the participants and secondly within
the broader context of health and social care research.
As this judgement necessarily appeals to moral norms, it
necessarily must be conducted by a committee of indi-
viduals constituted with (at least approximate) know-
ledge of current normative ethical values. This is a
complex task with the possibility of inconsistency, and it
is notable how well the UK Health Research Authority
(starting under its previous guise as the National Re-
search Ethics Service (NRES)) has been able to organise
and guide such reviews thanks to extensive training of
committee members, guidance such as the Governance
Arrangement for Research Ethics Committees (GAfREC)
[9] and Standard Operating Procedures (SOPs) [10].
Additionally it should also be noted that RECs are made
up of volunteers often reviewing studies in their spare
time and not always supported by their employers. HRA
coordinated RECs now review projects within strict
timeframes: 60 days for full review of complex projects
or 21 days for simpler ones. These timeframes are moni-
tored by a virtual clock to ensure that they are not brea-
ched, with the clock temporarily halted while awaiting
any required responses from applicants. Although there
is still room to improve the consistency of these reviews,
and of course there is almost always room for adminis-
trative fine tuning, this nationalised process is currently
robust and efficient. We feel that by confusing this ethics
review with other aspects of research governance (de-
scribed below), Petrova and Barclay significantly misrep-
resent the current ethics review process. For instance,
the authors repeatedly use the word “ethics approvals”.
Although we accept that this term is widely used with
reference to research ethics committee review (and in-
deed the HRA uses the word “approval” to refer to both
the ethics review and the governance review combined)
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research ethics committees themselves do not have the
authority to approve projects. Instead they offer an
opinion as to whether a piece of research is ethically
acceptable if conducted in accordance with the protocol
under review (see GAfREC chapter 5 [9]). It is then a
subsequent governance decision whether or not to “ap-
prove” the protocol taking into account the ethics com-
mittee opinion as well as other legal and policy
considerations. Petrova and Barclay perpetuate this com-
mon misunderstanding.
Research governance
Research governance is related to research ethics, but
operates under a different philosophy and using different
methods. While research ethics committee examine the
protocol and give an opinion in light of ethical princi-
ples, research governance focusses on the duties re-
quired of the researchers and organisations conducting
the research. Such duties are often reflected in the form
of laws and policies, and thus require assessment by re-
search officers (often based in University, NHS Trust or
company Research and Development (R&D) offices) with
expertise in areas such as law (clinical trial regulations,
radiation legislation etc.), employment contracts, insur-
ance and indemnity, risk assessment and often local
knowledge of practical issues inherent to conducting re-
search in busy clinical environments. Here again the
HRA has attempted to significantly streamline the
process by introducing its nation-wide “HRA Assess-
ment process”, something that was not yet in full swing
when Petrova and Barclay were conducting their work.
Indeed in response to Petrova and Barclay the HRA have
stated [11]:
We acknowledge and recognise the frustrations
experienced by the researchers in the paper, which
may be familiar to anyone who submitted a study
before HRA Approval was implemented in 2016, but
would like to ensure that readers consider this in the
context of systems that were in place in 2013 and
those that are in place now, over five years later.
Having also engaged with the HRA systems as both
researchers and sponsors we wish to commend the
HRA for its efforts in this area of research govern-
ance, but also perhaps agree with Petrova and Bar-
clay’s sentiments that the process is not yet operating
effectively. Here the problem lies not with the HRA,
which is normally able to conduct a national govern-
ance review in a timely fashion, but rather with local
NHS Trust and university research departments.
These departments can either be acting as sponsor
(see below) or provide local approvals/permissions. As
originally envisaged the HRA assessment process was
designed to ensure that NHS Trust research offices
only addressed matters of local capacity and capability
by focusing on and resolving any issue that could be
dealt with centrally, but upon the roll out of HRA
Assessment we have certainly found that Hospital
Trusts in particular have been guilty of creating new
local processes that are responsible for the majority
of delays. We therefore fully accept the data described
in Table 1 of Petrova and Barclay's paper, and indeed
would add to that our experience in Portsmouth (one
of our researchers recorded similar data to that re-
ported by Petrova & Barclay) where we noted over
200 email exchanges outside the HRA Assessment
process when trying to initiate two projects with three
different NHS trusts. It is in this local governance as-
pect where significant improvements have yet to be
made. There is always a tension between national and
local processes, but if the decision has been made to
have a national level governance assessment, more
can and must be done to minimise local processes.
A second element of research governance comes from
interactions between the researcher and the research
sponsor (whose roles are clearly defined in the UK policy
framework for health and social care research [12]). The
research sponsor role is particularly important within
healthcare research as it provides the necessary institu-
tional support to individual researchers. Interactions
with the research sponsor are distinct from interactions
with the HRA or other external bodies. When NHS
Trusts act as sponsors they are often also the employers
of researchers, and thus many of the interactions fall
under normal employer-employee interactions. This is
therefore a distinct role from the NHS Trust providing
local project approvals. Likewise interactions with re-
search funders, or Clinical Research Networks, either in
the course of applying for research funding or subse-
quent contractual or policy requirements as the research
is developed, registered and conducted, again represents
a different part of the governance process. We feel it is
unfair to include these sponsor, funding and registration
processes as part of the “Research Approvals Iceberg”.
Melting the iceberg?
Petrova and Barclay’s paper concludes with six recom-
mendations for how the system can be improved. Many of
these have currently already been actioned (as described
in the HRA’s response to the article [11]), however they
are right to point out problems with study classification
where we agree that it can be unhelpful to distinguish “re-
search” from “audit” and “service evaluations” [13]. How-
ever, the distinction is a matter of policy for the pragmatic
reason that seeking to improve practice is an inherent part
of clinical and most professional activity. Of course this
does not mean that these related activities do not require
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close governance and ethics scrutiny, but as these activ-
ities are mostly carried out by individuals in their place of
work, they are more appropriately covered under normal
employment and clinical arrangements/contracts/indem-
nities. We do not, however, agree that there is scope for
coordination between different parts of the research
process such as funding applications, patient/participant
involvement (PPI) reviews and ethics forms. This is be-
cause grant reviews by funding bodies are conducted well
before a protocol for a clinical trial has been developed,
simply because the funding is required to employ the staff
to design the protocol. Likewise patient participant in-
volvement (PPI) is focussed on both setting priorities and
commenting on aspects of research design as part of
protocol development. Similar to the process of engaging
with the sponsor organisation, we would therefore argue
that both funding and PPI interactions are part of the
early research development process itself, not the “regula-
tory iceberg”. It is difficult to see how these types of review
can be combined with the research ethics committee or
governance reviews that require a finalised, well defined,
protocol.
In conclusion, the paper by Petrova and Barclay pro-
vides a good opportunity to critically evaluate the re-
search regulatory process in the UK. They are correct
that the overall regulatory process can be laborious and
highly frustrating, but by conflating the research ethics
“opinion”, research governance “approval” aspects, and
interactions with sponsors/funders/PPI groups, we feel
that they have not accurately identified the parts of the
system that can be most improved, and also directed un-
fair criticism at research ethics committees. We propose
the following alternative suggestions for seeing system
change:
1) Promote the distinction between research ethics
and research governance
2) Encourage employers to recognise and support staff
involvement in research ethics committees.
3) Ensure that the national Assessment process
captures all relevant governance processes thereby
minimising local processes.
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